Infectious Disease In-vitro Diagnostics

Infectious Disease In-vitro Diagnostics Market Outlook

The global infectious disease in-vitro diagnostics market is projected to reach USD 27.8 billion by 2035, with a compound annual growth rate (CAGR) of 9.2% during the forecast period from 2025 to 2035. The key growth factors driving this market include the rising incidence of infectious diseases, increasing healthcare expenditure, advancements in diagnostic technologies, the growing demand for rapid and accurate diagnostic tests, and the shifting focus towards preventive healthcare measures. The COVID-19 pandemic has also accelerated the demand for in-vitro diagnostics, highlighting their critical role in disease management and control, thus propelling market growth.

Growth Factor of the Market

The infectious disease in-vitro diagnostics market is witnessing significant growth due to several intertwined factors. Firstly, the increasing prevalence of infectious diseases such as HIV, hepatitis, tuberculosis, and influenza is stimulating demand for effective diagnostic solutions. The advancement in technologies, particularly molecular diagnostics and point-of-care testing, has enhanced the speed and accuracy of diagnostics, making them more appealing to healthcare providers and patients alike. Furthermore, the rising awareness of early detection and treatment of infectious diseases has led to a higher rate of testing, which in turn boosts market growth. Additionally, the expanding geriatric population, who are more susceptible to infectious illnesses, contributes to the rising demand for in-vitro diagnostics. Finally, the global focus on improving healthcare infrastructure and increasing investments in the healthcare sector are expected to foster market expansion over the next decade.

Key Highlights of the Market

• The market is expected to grow significantly, reaching approximately USD 27.8 billion by 2035.
• Rapid technological advancements are driving innovation in testing methodologies.
• Increased government and funding initiatives to combat infectious diseases enhance market prospects.
• The rising demand for point-of-care testing is transforming traditional diagnostic approaches.
• The prevalence of infectious diseases is prompting healthcare professionals to adopt more effective diagnostic solutions.

By Product Type

Immunoassays:

Immunoassays are a prominent segment in the infectious disease in-vitro diagnostics market, utilized for their ability to detect specific antigens or antibodies in a sample. This method is particularly valuable in diagnosing diseases such as HIV and hepatitis, where accurate detection is critical for treatment and management. The growth of this segment is significantly driven by advancements in technology, which have led to the development of more sensitive and specific tests. Moreover, the ease of use and rapid results provided by immunoassays have made them a popular choice for laboratories and healthcare facilities. These assays are increasingly being integrated into point-of-care settings, further expanding their reach and application in infectious disease diagnostics.

Molecular Diagnostics:

Molecular diagnostics is one of the fastest-growing segments in the infectious disease in-vitro diagnostics market due to its ability to provide precise and rapid results through techniques such as PCR (Polymerase Chain Reaction) and NGS (Next-Generation Sequencing). This technology allows for the detection of pathogens at a genetic level, which is crucial for diagnosing infections like tuberculosis and COVID-19. The increasing focus on personalized medicine and the demand for quick turnaround times in clinical settings contribute significantly to the growth of this market segment. Additionally, the rise in research initiatives aiming to develop advanced molecular diagnostic tools enhances market prospects, making molecular diagnostics a key driver of innovation in the infectious disease space.

Clinical Microbiology:

The clinical microbiology segment plays a pivotal role in the infectious disease in-vitro diagnostics market by focusing on the identification and characterization of microorganisms associated with infections. This segment is essential for understanding pathogen dynamics, leading to effective treatment strategies. Technological advancements in culture methods, antimicrobial susceptibility testing, and the integration of automation in laboratories are propelling the growth of clinical microbiology diagnostics. The trend towards rapid testing and the need for comprehensive microbial analysis in healthcare settings are expected to drive further demand in this segment, positioning it as a vital component of infectious disease management.

Point-of-Care Testing:

Point-of-care testing (POCT) is gaining tremendous traction in the infectious disease in-vitro diagnostics market due to its ability to provide immediate results at or near the site of patient care. This segment is particularly beneficial in emergency settings and rural areas where access to traditional laboratories may be limited. The increasing demand for rapid diagnostics, combined with advancements in testing technologies, has led to the development of portable and user-friendly testing devices. The ongoing global health challenges, particularly highlighted by the COVID-19 pandemic, have further accentuated the importance of POCT, as they enable timely decision-making in patient management, thereby enhancing treatment outcomes.

Others:

The 'Others' category encompasses various diagnostic products utilized in the management of infectious diseases that do not fall under the traditional segments mentioned. This includes various emerging technologies and novel diagnostic assays that are being developed to address specific infectious challenges. The growth in this segment is propelled by the constant research and development efforts aimed at improving diagnostic capabilities. Innovations such as microfluidics and biosensors are contributing to the broadening of diagnostic options available to healthcare providers. The rising need to address niche infections and the customization of diagnostic solutions further bolster the growth of this segment, making it crucial in the fight against infectious diseases.

By Application

HIV:

HIV diagnostics remain a critical focus within the infectious disease in-vitro diagnostics market due to the global prevalence of the virus and the urgent need for early detection and management. Various diagnostic tests, including rapid tests and confirmatory assays, are designed to identify HIV infections effectively. The increasing awareness and screening initiatives by governments and non-governmental organizations significantly contribute to the growth of this application segment. Furthermore, the focus on treatment regimens such as antiretroviral therapy necessitates ongoing monitoring of viral loads and resistance testing, driving demand for advanced diagnostic solutions specific to HIV.

Hepatitis:

The hepatitis application segment is crucial in the infectious disease in-vitro diagnostics market, especially considering the high global prevalence of hepatitis B and C viruses. Diagnostic tests, including serological assays and molecular tests, are vital for the early detection and management of these infections. The rising awareness of viral hepatitis and the need for regular screening among at-risk populations are significant growth drivers. Additionally, the expanding availability of vaccines and therapies for hepatitis is expected to further boost the demand for diagnostic tests. As healthcare systems increasingly prioritize the elimination of hepatitis, the focus on developing more efficient and accurate diagnostics will continue to grow.

Influenza:

Influenza diagnostics are essential for timely identification and management of influenza infections, particularly during seasonal outbreaks. The increasing incidence of influenza and the associated healthcare burden drive demand for rapid diagnostic tests, such as rapid influenza diagnostic tests (RIDTs) and PCR-based assays. The growth of this application segment is further supported by the rising emphasis on early diagnosis to initiate appropriate antiviral treatment and reduce transmission rates. Moreover, the advent of new influenza strains and the need for effective vaccine matching contribute to an ongoing necessity for accurate diagnostics, making this segment a key area of focus in infectious disease management.

Tuberculosis:

Tuberculosis (TB) diagnostics are critical given the global burden of this infectious disease, particularly in developing regions. The increasing incidence of drug-resistant TB strains necessitates advanced diagnostic tools that can provide rapid and accurate results. Molecular diagnostics, such as GeneXpert, have revolutionized TB testing by allowing for quick identification of Mycobacterium tuberculosis and drug susceptibility testing. The global initiatives aimed at TB elimination, including increased funding and awareness campaigns, are significant drivers of growth in this application segment. As more patients are diagnosed and treated effectively, the demand for innovative diagnostics in TB management is expected to rise steadily.

Others:

The 'Others' category in application segmentation includes various infectious diseases that require diagnostic solutions but do not fit into the primary categories such as HIV, hepatitis, influenza, or tuberculosis. This segment encompasses a wide range of diseases, including but not limited to sexually transmitted infections (STIs), emerging infectious diseases, and zoonotic diseases. The growth in this segment is fueled by the increasing awareness of various infectious threats and the need for comprehensive screening strategies. Technological innovations and research advancements are contributing to the ongoing development of diagnostic tests tailored to these lesser-known infectious diseases, which is critical for effective public health responses.

By Distribution Channel

Hospitals:

Hospitals represent a significant distribution channel for infectious disease in-vitro diagnostics, accounting for a large portion of the market share. The increasing number of hospital admissions due to infectious diseases necessitates the availability of rapid and accurate diagnostic tests within these facilities. Hospitals are equipped with advanced laboratory facilities that can conduct a broad range of diagnostic tests, ensuring timely diagnosis and treatment of patients. The integration of sophisticated laboratory information systems enhances the efficiency of diagnostic processes, making hospitals a preferred choice for diagnostics. Moreover, the ongoing expansion of healthcare infrastructure and the rising patient population are expected to further bolster the growth of this distribution channel.

Laboratories:

Laboratories are a crucial distribution channel for infectious disease in-vitro diagnostics, encompassing both independent laboratories and those affiliated with hospitals. The rise in demand for specialized testing and advanced diagnostics contributes significantly to the growth of this segment. Independent laboratories offer flexibility and often employ the latest technologies, providing a range of testing options to healthcare providers. Additionally, the trend towards outsourcing laboratory services by hospitals is promoting the establishment of specialized diagnostic centers. Increased investments in laboratory infrastructure and technology advancements are expected to drive the growth of this distribution channel, enabling more efficient and accurate diagnostics for infectious diseases.

Academic and Research Institutes:

Academic and research institutes play a pivotal role in the dissemination of knowledge and advancement of technologies in the field of infectious disease diagnostics. These institutions are often at the forefront of innovative research, developing new diagnostic methodologies and contributing to the validation of existing tests. Furthermore, the collaboration between these institutions and healthcare organizations enhances the translation of research into practical applications. As the focus on infectious diseases intensifies globally, the role of academic and research institutes in developing and providing access to novel diagnostic solutions is expected to grow. Their contributions are crucial for improving diagnostic accuracy and expanding the range of tests available for infectious disease management.

Others:

The 'Others' category within distribution channels encompasses various avenues through which infectious disease in-vitro diagnostics are made available to healthcare providers and patients. This includes online platforms, direct-to-consumer sales, and specialized clinics that offer diagnostic testing. The growth of e-commerce in healthcare, fueled by the increasing consumer demand for home-based and rapid testing solutions, is significantly impacting this segment. These alternative distribution channels provide convenience and accessibility, particularly in regions where traditional healthcare facilities may be limited. The ongoing digital transformation of the healthcare sector is expected to further enhance the growth of this distribution channel, making diagnostics more widely available to those in need.

By Technology Type

PCR:

Polymerase Chain Reaction (PCR) technology is a cornerstone of molecular diagnostics in the infectious disease in-vitro diagnostics market. Its ability to amplify small segments of DNA has made it an indispensable tool for the detection of a wide variety of pathogens, including viruses, bacteria, and parasites. PCR-based tests are known for their high sensitivity and specificity, making them the preferred choice for diagnosing infections such as COVID-19 and tuberculosis. The ongoing advancements in PCR technology, including real-time PCR and digital PCR, are enhancing diagnostic accuracy and reducing time to results. As the demand for rapid and reliable diagnostics continues to grow, PCR is expected to maintain its significant share in the technology type segment of the market.

Immunoassays:

Immunoassays are widely utilized in the infectious disease in-vitro diagnostics market due to their effectiveness in detecting specific antigens and antibodies. These assays are critical in diagnosing various infectious diseases, including HIV, hepatitis, and influenza. The growth of immunoassays is driven by advancements in assay technology, which have led to the development of more sensitive and rapid tests. The ease of use and rapid turnaround times associated with immunoassays make them suitable for both laboratory and point-of-care settings. As the healthcare industry increasingly prioritizes rapid diagnostics, immunoassays are expected to continue their upward trajectory, becoming an essential component of infectious disease management.

Microarrays:

Microarray technology offers a powerful platform for simultaneous detection of multiple pathogens in infectious disease diagnostics. This technology enables the analysis of gene expression and the identification of various infectious agents in a single test, significantly enhancing diagnostic capabilities. The growth of the microarrays segment is fueled by the increasing need for comprehensive testing, particularly in complex cases involving co-infections. As healthcare providers strive to improve patient outcomes through more accurate and efficient diagnostics, the adoption of microarray technology is expected to grow. Furthermore, advancements in bioinformatics and data analysis are enhancing the utility of microarrays in infectious disease diagnostics.

Sequencing:

Sequencing technologies, including next-generation sequencing (NGS), are becoming increasingly important in the infectious disease in-vitro diagnostics market due to their ability to provide detailed genetic information about pathogens. This technology facilitates the identification of drug-resistant strains and helps in tracking outbreaks, making it a valuable tool for public health surveillance. The growth of the sequencing segment is driven by the rising demand for personalized medicine and targeted therapies, as well as the need for comprehensive testing to combat evolving infectious threats. As the technology becomes more accessible and cost-effective, its adoption in routine diagnostics is expected to rise significantly.

Others:

The 'Others' category in technology types includes various emerging diagnostic technologies that do not fit within the traditional categories such as PCR, immunoassays, and sequencing. This segment encompasses innovative approaches such as CRISPR-based diagnostics, biosensors, and microfluidics, which are gaining traction in the infectious disease diagnostics market. The development of these novel technologies is driven by the need for more efficient, rapid, and accurate diagnostic solutions. As research continues to advance in this area, the 'Others' segment is expected to grow, contributing to the diversification of diagnostic options available for infectious disease management.

By Region

The infectious disease in-vitro diagnostics market is experiencing significant growth across various regions, with North America being a prominent leader. In 2023, North America accounted for approximately 40% of the global market share, driven by the presence of advanced healthcare infrastructure, high levels of investment in research and development, and the increasing number of infectious disease cases. The United States, in particular, is a key contributor to this growth, with ongoing government initiatives aimed at improving diagnostic capabilities and access to healthcare services. The focus on preventive healthcare and early disease detection is expected to further enhance the market landscape in this region, with a projected CAGR of 8.5% during the forecast period.

Europe follows closely as another major player in the infectious disease in-vitro diagnostics market, holding approximately 30% of the global market share. The region benefits from a well-established healthcare system, with increasing funding for research and innovation in diagnostics. Countries such as Germany, France, and the UK are investing heavily in diagnostic technologies, aiming to enhance their capabilities in managing infectious diseases. The rising incidence of infectious diseases, coupled with the aging population, is expected to boost demand for effective diagnostics in Europe. The market in this region is anticipated to grow at a CAGR of 7.8%, driven by advancements in technology and increasing awareness about infectious disease prevention.

Opportunities

The infectious disease in-vitro diagnostics market presents numerous opportunities for growth and innovation, particularly in the realm of technological advancements. As healthcare providers increasingly seek rapid and reliable diagnostic solutions, there is an opportunity for companies to develop cutting-edge technologies that enhance testing accuracy and turnaround times. The integration of artificial intelligence and machine learning into diagnostic processes offers significant potential for improving disease detection and management. Additionally, the ongoing globalization of health challenges, such as pandemics, necessitates the development of scalable and adaptable diagnostic solutions capable of meeting diverse regional needs. Companies focusing on these technological innovations are well-positioned to capitalize on the growing demand for effective infectious disease diagnostics.

Moreover, there is an opportunity to expand access to in-vitro diagnostics in underserved regions, where access to healthcare services may be limited. Companies that invest in outreach initiatives and partnerships with local health organizations can play a pivotal role in improving diagnostic capabilities in these areas. Furthermore, the increasing focus on preventive healthcare and early disease detection opens avenues for collaboration between diagnostic companies, healthcare providers, and public health agencies. As the global emphasis on health equity and accessible healthcare continues to grow, opportunities to address infectious disease challenges through innovative and accessible diagnostic solutions will expand significantly.

Threats

The infectious disease in-vitro diagnostics market faces several threats that could impact growth and stability. One of the primary threats is the rapid evolution of pathogens and the emergence of drug-resistant strains, which pose challenges to existing diagnostic methodologies. The increasing prevalence of antimicrobial resistance (AMR) complicates the detection and treatment of infectious diseases, necessitating the continuous development of advanced diagnostic tools. Additionally, the high costs associated with developing and validating new diagnostic tests can pose a barrier to entry for smaller companies, limiting competition and innovation in the market. Furthermore, regulatory challenges and the need for compliance with stringent healthcare standards can create hurdles for market players, particularly in the context of global health initiatives.

Moreover, the ongoing impact of economic fluctuations, particularly in the wake of global health crises, can affect healthcare budgets and funding for diagnostic programs. In regions where healthcare resources are limited, the prioritization of diagnostics may face challenges, adversely affecting market growth. Furthermore, global supply chain disruptions, as witnessed during the COVID-19 pandemic, can impact the availability of diagnostic products and reagents, leading to delays in testing and diagnosis. These threats underscore the importance of resilience and adaptability in the infectious disease in-vitro diagnostics market, necessitating a proactive approach to addressing emerging challenges.

Competitor Outlook

• Roche Diagnostics
• Abbott Laboratories
• Thermo Fisher Scientific Inc.
• Siemens Healthineers
• bioMérieux SA
• BD Diagnostics
• Hologic, Inc.
• Cepheid, Inc.
• QIAGEN N.V.
• Ortho Clinical Diagnostics
• Danaher Corporation
• PerkinElmer, Inc.
• Grifols S.A.
• F. Hoffmann-La Roche Ltd.
• AbbVie Inc.

The competitive landscape of the infectious disease in-vitro diagnostics market is characterized by a mix of established players and emerging companies striving for market share. Major companies like Roche Diagnostics and Abbott Laboratories dominate the market, leveraging their extensive research capabilities, strong distribution networks, and comprehensive product portfolios. These industry leaders are continually investing in research and development to innovate and refine diagnostic technologies, ensuring they maintain a competitive edge. Additionally, strategic collaborations and partnerships among companies, academic institutions, and healthcare organizations are becoming increasingly common, facilitating the development of new diagnostic solutions and expanding market reach.

Emerging companies within the infectious disease diagnostics space are also making significant strides, often focusing on niche markets or novel technologies. For instance, startups specializing in rapid testing solutions or point-of-care diagnostics are gaining traction in response to the growing demand for quick and accessible testing options. These companies are often agile and capable of adapting to changing market needs more swiftly than larger organizations, positioning them as formidable competitors. As the market for infectious disease diagnostics continues to evolve, the distinction between established players and innovative newcomers is likely to shape the competitive landscape in the coming years.

Key players such as Thermo Fisher Scientific, Siemens Healthineers, and bioMérieux are notable for their extensive portfolios and global presence. Thermo Fisher Scientific, for example, is known for its advanced molecular diagnostic solutions, including PCR tests that are essential for detecting a range of infectious diseases. Siemens Healthineers focuses on integrating digital solutions with traditional diagnostic methods, enhancing both efficiency and accuracy in laboratory settings. Meanwhile, bioMérieux is recognized for its expertise in microbiology and rapid diagnostics, continuously expanding its offerings to meet the demands of the ever-evolving infectious disease landscape. Together, these companies represent the forefront of innovation in infectious disease diagnostics, shaping the future of healthcare through their commitment to research, development, and collaboration.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 AbbVie Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 QIAGEN N.V.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Grifols S.A.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Cepheid, Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Hologic, Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 BD Diagnostics
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 PerkinElmer, Inc.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Roche Diagnostics
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Abbott Laboratories
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Danaher Corporation
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Siemens Healthineers
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 bioMérieux SA
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 F. Hoffmann-La Roche Ltd.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Ortho Clinical Diagnostics
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Thermo Fisher Scientific Inc.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Infectious Disease In-vitro Diagnostics Market, By Product Type
    • 6.1.1 Immunoassays
    • 6.1.2 Molecular Diagnostics
    • 6.1.3 Clinical Microbiology
    • 6.1.4 Point-of-Care Testing
    • 6.1.5 Others
  • 6.2 Infectious Disease In-vitro Diagnostics Market, By Distribution Channel
    • 6.2.1 Hospitals
    • 6.2.2 Laboratories
    • 6.2.3 Academic and Research Institutes
    • 6.2.4 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Infectious Disease In-vitro Diagnostics Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Infectious Disease In-vitro Diagnostics market is categorized based on

By Product Type

• Immunoassays
• Molecular Diagnostics
• Clinical Microbiology
• Point-of-Care Testing
• Others

By Distribution Channel

• Hospitals
• Laboratories
• Academic and Research Institutes
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Roche Diagnostics
• Abbott Laboratories
• Thermo Fisher Scientific Inc.
• Siemens Healthineers
• bioMérieux SA
• BD Diagnostics
• Hologic, Inc.
• Cepheid, Inc.
• QIAGEN N.V.
• Ortho Clinical Diagnostics
• Danaher Corporation
• PerkinElmer, Inc.
• Grifols S.A.
• F. Hoffmann-La Roche Ltd.
• AbbVie Inc.